Regulation of Bax/Bcl2 Gene Expression in Breast Cancer Cells by Docetaxel-Loaded Human Serum Albumin Nanoparticles Publisher Pubmed



Kordezangeneh M¹ ; Irani S¹ ; Mirfakhraie R² ; Esfandyarimanesh M³ ; Atyabi F^{3, 4} ; Dinarvand R^{3, 4}
Source: Medical Oncology Published:2015

Abstract

Today, using nanoparticle-based drug delivery systems has expanded to avoid anticancer side effects. Taxanes are important chemotherapeutic agents in the treatment of metastatic breast cancer. In this study, docetaxel (DTX)-loaded human serum albumin (HSA) nanoparticles (NPs) were prepared and characterized. Drug toxicity of the nanoparticles was measured by MTT assay with different drug concentrations (0.01, 0.1, 0.5, 1 and 5 μM) at different incubation times (24, 48 and 72 h). Expression of BAX/BCL2 mRNA levels was determined by real-time PCR. The size of NPs prepared and used in our study was about 147 nm with surface charge of −29.6 mV. Results obtained from MTT assay showed that 0.5 μM of free drug had 50 % toxicity on MCF-7 cells after 48-h incubation. Real-time PCR results showed an increase in expression of BAX and no change for BCL2. In conclusion, a significant overexpression of BAX gene and changes in BAX/BCL2 ratio were observed for DTX-loaded HSA nanoparticles compared with free DTX and may provide a potential therapy to inhibit anticancer drug resistance. © 2015, Springer Science+Business Media New York.